These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

706 related items for PubMed ID: 7522954

  • 1. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
    Zambello R, Trentin L, Cerutti A, Enthammer C, Milani A, Franceschi T, Messina C, Cetto GL, Agostini C, Semenzato G.
    Cancer; 1994 Nov 01; 74(9):2562-9. PubMed ID: 7522954
    [Abstract] [Full Text] [Related]

  • 2. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
    Gratama JW, Bruin RJ, Lamers CH, Oosterom R, Braakman E, Stoter G, Bolhuis RL.
    Clin Exp Immunol; 1993 May 01; 92(2):185-93. PubMed ID: 8485906
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Expression of p75 chain of IL-2 receptor in the early immunological reconstitution after allogeneic bone marrow transplantation.
    Comoli P, Maccario R, Montagna D, Labirio M, Zecca M, Clementi R, Bonetti F, Locatelli F.
    Clin Exp Immunol; 1994 Sep 01; 97(3):510-6. PubMed ID: 8082308
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
    Martí F, Pardo N, Peiró M, Bertran E, Amill B, García J, Cubells J, Rueda F.
    Exp Hematol; 1995 Dec 01; 23(14):1445-52. PubMed ID: 8542930
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells.
    Baume DM, Robertson MJ, Levine H, Manley TJ, Schow PW, Ritz J.
    Eur J Immunol; 1992 Jan 01; 22(1):1-6. PubMed ID: 1370410
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation.
    Soiffer RJ, Murray C, Cochran K, Cameron C, Wang E, Schow PW, Daley JF, Ritz J.
    Blood; 1992 Jan 15; 79(2):517-26. PubMed ID: 1730094
    [Abstract] [Full Text] [Related]

  • 20. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L, Fenchel K, Weidmann E, Enzinger HM, Jahn B, Jonas D, Mitrou PS.
    Cancer; 1993 Sep 01; 72(5):1733-42. PubMed ID: 8348502
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.